Spermosens AB (publ)
Spermosens AB (publ) provides diagnostic health care products and services in Sweden. The company offers devices for male infertility for fertility diagnostics and treatments for the IVF market. It develops JUNO-Checked, a device that measures the binding between sperm and egg cell to enable individualized choice of fertility treatment based on measured binding. Spermosens AB (publ) was incorpora… Read more
Spermosens AB (publ) (9R5) - Net Assets
Latest net assets as of September 2025: €34.52 Million EUR
Based on the latest financial reports, Spermosens AB (publ) (9R5) has net assets worth €34.52 Million EUR as of September 2025.
Net assets (also known as shareholders' equity or book value) represent the difference between a company's total assets (€35.59 Million) and total liabilities (€1.06 Million). This figure indicates the residual interest in the assets after deducting liabilities, essentially showing what would remain for shareholders if all assets were liquidated and all debts paid off.
Key Net Assets Metrics
| Metric | Value |
|---|---|
| Current Net Assets | €34.52 Million |
| % of Total Assets | 97.01% |
| Annual Growth Rate | 4.97% |
| 5-Year Change | N/A |
| 10-Year Change | N/A |
| Growth Volatility | 90.48 |
Spermosens AB (publ) - Net Assets Trend (2021–2024)
This chart illustrates how Spermosens AB (publ)'s net assets have evolved over time, based on quarterly financial data. Explore and compare other companies by net assets.
Annual Net Assets for Spermosens AB (publ) (2021–2024)
The table below shows the annual net assets of Spermosens AB (publ) from 2021 to 2024.
| Year | Net Assets | Change |
|---|---|---|
| 2024-12-31 | €27.34 Million | +115.45% |
| 2023-12-31 | €12.69 Million | +117.74% |
| 2022-12-31 | €5.83 Million | -75.34% |
| 2021-12-31 | €23.64 Million | -- |
Equity Component Analysis
This analysis shows how different components contribute to Spermosens AB (publ)'s total equity over time. Equity components include common stock, retained earnings, additional paid-in capital, and other elements.
Equity Composition Insights
- Retained earnings have decreased by 6483900000.0% over the analyzed period, potentially due to dividend distributions or operating losses.
Current Equity Component Breakdown (December 2024)
| Component | Amount | Percentage |
|---|---|---|
| Other Components | €118.92 Million | 434.88% |
| Total Equity | €27.34 Million | 100.00% |
Spermosens AB (publ) Competitors by Market Cap
The table below lists competitors of Spermosens AB (publ) ranked by their market capitalization.
| Company | Market Cap |
|---|---|
|
RJK Explorations Ltd
PINK:RJKAF
|
$517.37K |
|
Burcon NutraScience Corp
PINK:BRCNF
|
$518.20K |
|
Cymbria Corporation
PINK:CYMBF
|
$518.44K |
|
Silver Sands Resources Corp
PINK:SSRSF
|
$518.45K |
|
Longevity Health Holdings, Inc.
NASDAQ:XAGE
|
$516.88K |
|
HAEMONETICS
MU:HAZ
|
$516.82K |
|
Movinn AS
CO:MOVINN
|
$516.79K |
|
Iiot-Oxys Inc
PINK:ITOX
|
$516.62K |
Equity Growth Attribution
This analysis shows how different factors contributed to changes in Spermosens AB (publ)'s equity between the two most recent reporting periods.
Equity Growth Insights
- From 2023 to 2024, total equity changed from 12,692,000 to 27,345,000, a change of 14,653,000 (115.5%).
- Net loss of 10,204,000 reduced equity.
- New share issuances of 9,115,000 increased equity.
- Other factors increased equity by 15,742,000.
Equity Change Factors (2023 to 2024)
| Factor | Impact | Contribution |
|---|---|---|
| Net Income | €-10.20 Million | -37.32% |
| Share Issuances | €9.12 Million | +33.33% |
| Other Changes | €15.74 Million | +57.57% |
| Total Change | €- | 115.45% |
Book Value vs Market Value Analysis
This analysis compares Spermosens AB (publ)'s book value (net assets) with its market value over time. The relationship between these values can provide insights into investor sentiment and company valuation.
Valuation Insights
- Current price-to-book ratio: 0.01x
- The company is trading below its book value, potentially indicating the market believes the assets are overvalued on the balance sheet or anticipates future losses.
Historical Price-to-Book Ratios
| Date | Book Value per Share | Market Price | P/B Ratio |
|---|---|---|---|
| 2021-12-31 | €0.29 | €0.00 | x |
| 2022-12-31 | €0.06 | €0.00 | x |
| 2023-12-31 | €0.06 | €0.00 | x |
| 2024-12-31 | €0.04 | €0.00 | x |
Capital Efficiency Dashboard
This dashboard shows how efficiently Spermosens AB (publ) utilizes its equity to generate returns, including Return on Equity (ROE) and its components based on the DuPont analysis framework.
Capital Efficiency Insights
- Current Return on Equity (ROE): -37.32%
- The company may be facing challenges in efficiently utilizing shareholder equity.
- DuPont Analysis Breakdown:
- • Net Profit Margin: 0.00%
- • Asset Turnover: 0.00x
- • Equity Multiplier: 1.14x
- Recent ROE (-37.32%) is above the historical average (-122.47%), indicating improving capital efficiency.
Historical Capital Efficiency Metrics
| Year | Return on Equity | Net Profit Margin | Asset Turnover | Equity Multiplier | Economic Value Added |
|---|---|---|---|---|---|
| 2021 | -27.17% | -16902.63% | 0.00x | 1.09x | €-8.79 Million |
| 2022 | -329.25% | 0.00% | 0.00x | 1.66x | €-19.77 Million |
| 2023 | -96.14% | 0.00% | 0.00x | 2.06x | €-13.47 Million |
| 2024 | -37.32% | 0.00% | 0.00x | 1.14x | €-12.94 Million |
Industry Comparison
This section compares Spermosens AB (publ)'s net assets metrics with peer companies in the Diagnostics & Research industry.
Industry Context
- Industry: Diagnostics & Research
- Average net assets among peers: $12,331,149,067
- Average return on equity (ROE) among peers: -34.27%
Peer Company Comparison
| Company | Net Assets | Return on Equity | Debt-to-Equity | Market Cap |
|---|---|---|---|---|
| Spermosens AB (publ) (9R5) | €34.52 Million | -27.17% | 0.03x | $517.28K |
| BML Inc (BMZ) | $81.13 Billion | 8.19% | 0.43x | $462.01 Million |
| Genomic Vision Société Anonyme (G09) | $3.07 Million | -162.85% | 1.21x | $711.54K |
| ICON Public Limited Company (IJF) | $1.85 Billion | 17.96% | 0.86x | $6.43 Billion |
| Adicon Holdings Limited (K0U) | $1.77 Billion | 2.65% | 1.64x | $138.53 Million |
| WuXi XDC Cayman Inc. (L74) | $1.48 Billion | 10.52% | 0.69x | $2.11 Billion |
| NanoRepro AG (NN6) | $57.61 Million | 51.59% | 0.37x | $16.84 Million |
| PERRIGO (PGO) | $24.67 Million | -167.93% | 0.99x | $6.37K |